Public Employees Retirement System of Ohio Reduces Stock Position in DexCom, Inc. (NASDAQ:DXCM)

Public Employees Retirement System of Ohio trimmed its holdings in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 7.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 134,704 shares of the medical device company's stock after selling 11,219 shares during the quarter. Public Employees Retirement System of Ohio's holdings in DexCom were worth $10,476,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in DXCM. Forvis Mazars Wealth Advisors LLC raised its holdings in shares of DexCom by 0.7% during the 4th quarter. Forvis Mazars Wealth Advisors LLC now owns 17,481 shares of the medical device company's stock worth $1,359,000 after buying an additional 118 shares in the last quarter. Principal Securities Inc. lifted its holdings in shares of DexCom by 3.4% during the fourth quarter. Principal Securities Inc. now owns 4,069 shares of the medical device company's stock worth $316,000 after purchasing an additional 135 shares during the period. Larson Financial Group LLC grew its position in shares of DexCom by 40.5% in the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock valued at $37,000 after buying an additional 137 shares during the last quarter. Nia Impact Advisors LLC raised its position in shares of DexCom by 1.4% during the fourth quarter. Nia Impact Advisors LLC now owns 9,850 shares of the medical device company's stock worth $766,000 after acquiring an additional 140 shares during the last quarter. Finally, Level Four Advisory Services LLC lifted its position in shares of DexCom by 1.1% in the 4th quarter. Level Four Advisory Services LLC now owns 13,196 shares of the medical device company's stock worth $1,026,000 after purchasing an additional 150 shares during the period. 97.75% of the stock is owned by institutional investors.

DexCom Price Performance

NASDAQ DXCM traded down $2.12 during trading on Thursday, reaching $84.86. The company's stock had a trading volume of 3,611,089 shares, compared to its average volume of 4,364,142. The firm has a fifty day moving average of $74.23 and a 200 day moving average of $78.47. DexCom, Inc. has a one year low of $57.52 and a one year high of $128.63. The stock has a market capitalization of $33.27 billion, a PE ratio of 59.34, a P/E/G ratio of 2.30 and a beta of 1.43. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical device company reported $0.32 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.01). The company had revenue of $1.04 billion during the quarter, compared to the consensus estimate of $1.02 billion. DexCom had a return on equity of 30.14% and a net margin of 14.29%. The firm's revenue for the quarter was up 12.5% on a year-over-year basis. During the same quarter last year, the company posted $0.32 earnings per share. Analysts expect that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Insider Buying and Selling at DexCom

In other news, EVP Sadie Stern sold 6,184 shares of the stock in a transaction dated Tuesday, May 27th. The stock was sold at an average price of $85.11, for a total transaction of $526,320.24. Following the transaction, the executive vice president now directly owns 109,621 shares in the company, valued at approximately $9,329,843.31. This represents a 5.34% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Jereme M. Sylvain sold 7,000 shares of the business's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $73.83, for a total value of $516,810.00. Following the completion of the sale, the executive vice president now owns 135,482 shares of the company's stock, valued at $10,002,636.06. The trade was a 4.91% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 83,110 shares of company stock worth $6,103,505 over the last 90 days. Corporate insiders own 0.32% of the company's stock.

Analysts Set New Price Targets

Several analysts have recently weighed in on DXCM shares. Mizuho began coverage on shares of DexCom in a research note on Thursday, April 10th. They issued an "outperform" rating and a $85.00 price objective for the company. Wells Fargo & Company restated an "overweight" rating on shares of DexCom in a research note on Saturday, March 8th. Robert W. Baird dropped their price target on shares of DexCom from $115.00 to $105.00 and set an "outperform" rating on the stock in a research report on Friday, May 2nd. Canaccord Genuity Group increased their target price on shares of DexCom from $103.00 to $106.00 and gave the company a "buy" rating in a report on Friday, May 2nd. Finally, Cfra Research raised DexCom to a "hold" rating in a research report on Friday, March 21st. Five investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat, DexCom currently has a consensus rating of "Moderate Buy" and a consensus target price of $98.00.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.